# Wondfo Biotech

Wondfo Biotech is an Asset Manager based in Guangzhou, China.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Guangzhou, China
- **Region:** Europe
- **Address:** No.8 Lizhishan Road, Science City, Huangpu, Guangzhou, China
- **Assets under management:** Undisclosed
- **Website:** wondfo.com
- **LinkedIn:** https://www.linkedin.com/company/wondfo

## Regulatory record

- **Reports private funds:** No

## About

Guangzhou Wondfo Biotech Co., Ltd. manufactures POCT products. Its operations cover research and development, production, sales, and repair of those products. It provides customers with unwellness management.

## Sectors

- Digital Health

## Offices

- Schaffhausen, Switzerland
- Basel, Switzerland
- Amsterdam, Netherlands
- Wien, Austria
- Hemel Hempstead, United Kingdom
- Minneapolis, United States

## Questions

### What diagnostic platforms does Wondfo Biotech operate?

Wondfo organizes its technology stack into eight platforms: colloidal gold, immunofluorescence, chemiluminescence, coagulation, blood gas, molecular diagnostics, pathology, and HPLC hemoglobin analysis. The firm claims its optical coagulation analyzer is the first to test PT, APTT, TT, FIB, and ACT simultaneously. These platforms support over 50 reagent categories and five device types, covering infectious disease, fertility, cardiovascular markers, and diabetes.

### Does Wondfo Biotech participate in fund commitments or operate as an investment vehicle?

Wondfo Biotech operates as a publicly traded operating company, not a family office, fund, or investment vehicle. Its structure centers on R&D, manufacturing, and distribution of diagnostic products. The firm does not publicly disclose a capital-allocation program, fund commitments, or a separate investment arm accessible to external limited partners.

### What role did COVID-19 diagnostics play in Wondfo's recent expansion?

During the pandemic, Wondfo developed lyophilized RT-PCR reagents and secured WHO prequalification for an infectious-disease rapid diagnostic test, accelerating its international public-health visibility. The firm marketed a COVID-19 Total Solution and used the surge in PCR demand to broaden its molecular-diagnostics platform adoption outside China.

### Is Wondfo Biotech's leadership team publicly disclosed?

English-language corporate materials on Wondfo's website do not include a named leadership team, board biographies, or an investment committee roster. The firm references 800-plus researchers and a 3,800-employee base but provides no public organizational chart or principal biographies for English-speaking allocators.

## Related profiles

- [Guangdong Sanjiang United Fund Management](https://altss.com/profile/guangdong-sanjiang-united-fund-management)
- [GUANILL WEALTH MANAGEMENT](https://altss.com/profile/guanill-wealth-management)

---

Last updated: 2026-07-11T16:25:13.000Z

Canonical page: https://altss.com/profile/guangzhou-wondfo-biotech-co-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology